Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew P Goetz

Showing results (241-250 of 265) with videos related to

Pageof 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 7, 2017
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast CancerCynthia X Ma, Vera Suman, Matthew P Goetz, et al.
Journal of the National Cancer Institute|April 5, 2017
Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast CancerMatthew P Goetz, Krishna R Kalari, Vera J Suman, et al.
Breast Cancer Research and Treatment|August 23, 2015
Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapyMarissa S Ellingson, Steven N Hart, Krishna R Kalari, et al.
Breast Cancer Research and Treatment|August 17, 2023
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypesLauren Lenz, Chris Neff, Cara Solimeno, et al.
JAMA Oncology|October 1, 2019
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical TrialJoseph A Sparano, Robert J Gray, Della F Makower, et al.
Journal of the National Cancer Institute|September 28, 2020
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx TrialKathy S Albain, Robert J Gray, Della F Makower, et al.
JAMA|April 2, 2024
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerRoberto A Leon-Ferre, Sarah Flora Jonas, Roberto Salgado, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 14, 2017
NCCN Guidelines Insights: Breast Cancer, Version 1.2017William J Gradishar, Benjamin O Anderson, Ron Balassanian, et al.
The New England Journal of Medicine|June 4, 2019
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast CancerJoseph A Sparano, Robert J Gray, Peter M Ravdin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 8, 2020
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyWilliam J Gradishar, Benjamin O Anderson, Jame Abraham, et al.
Pageof 27

Showing results (241-250 of 265) with videos related to

Sort By:
Pageof 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 7, 2017
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast CancerCynthia X Ma, Vera Suman, Matthew P Goetz, et al.
Journal of the National Cancer Institute|April 5, 2017
Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast CancerMatthew P Goetz, Krishna R Kalari, Vera J Suman, et al.
Breast Cancer Research and Treatment|August 23, 2015
Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapyMarissa S Ellingson, Steven N Hart, Krishna R Kalari, et al.
Breast Cancer Research and Treatment|August 17, 2023
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypesLauren Lenz, Chris Neff, Cara Solimeno, et al.
JAMA Oncology|October 1, 2019
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical TrialJoseph A Sparano, Robert J Gray, Della F Makower, et al.
Journal of the National Cancer Institute|September 28, 2020
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx TrialKathy S Albain, Robert J Gray, Della F Makower, et al.
JAMA|April 2, 2024
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerRoberto A Leon-Ferre, Sarah Flora Jonas, Roberto Salgado, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 14, 2017
NCCN Guidelines Insights: Breast Cancer, Version 1.2017William J Gradishar, Benjamin O Anderson, Ron Balassanian, et al.
The New England Journal of Medicine|June 4, 2019
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast CancerJoseph A Sparano, Robert J Gray, Peter M Ravdin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 8, 2020
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyWilliam J Gradishar, Benjamin O Anderson, Jame Abraham, et al.
Pageof 27